Evidence map›Paper›PMID 30535954›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2019

Treprostinil reduces endothelial damage in murine sinusoidal obstruction syndrome.

Madeleine Themanns, Florian Koban, Christian Bergmayr, Alicja Chrzan, Wolfgang Strohmaier, Johannes Haybaeck, Michael Freissmuth, Eva Zebedin-Brandl

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Madeleine ThemannsInstitute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Centre of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Florian KobanInstitute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Centre of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Christian BergmayrInstitute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Centre of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Alicja ChrzanDepartment of Pathology, University Hospital and Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Wolfgang StrohmaierSciPharm SàRL, 2540, Luxembourg City, Luxembourg.
Johannes HaybaeckDepartment of Pathology, University Hospital and Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Michael FreissmuthInstitute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Centre of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Eva Zebedin-BrandlInstitute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Centre of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. eva-maria.zebedin@meduniwien.ac.at.
Medical University of Vienna · ATOtto-von-Guericke University Magdeburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sinusoidal obstruction syndrome (SOS) is a major complication after hematopoietic stem cell transplantation and belongs to a group of diseases increasingly identified as transplant-related systemic endothelial disease. Administration of defibrotide affords some protection against SOS, but the effect is modest. Hence, there is unmet medical need justifying the preclinical search for alternative approaches. Prostaglandins exert protective actions on endothelial cells of various vascular beds. Here, we explored the therapeutic potential of the prostacyclin analog treprostinil to prevent SOS. Treprostinil acts via stimulation of IP, EP

Indexed as

AnimalsCell DeathCytoprotectionEndothelial CellsEpoprostenolHematopoietic Stem Cell TransplantationHepatic Veno-Occlusive DiseaseMaleMiceMice, Inbred BALB CMice, Inbred C57BLProtective AgentsEpoprostenolProtective AgentstreprostinilDefibrotideHSCTProstacyclinSOSTransplant-related toxicityVOD

Identifiers

PMID30535954
PMCPMC6348071
OpenAlexW2904723953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.